Showing 4781-4790 of 5806 results for "".
- UCB Presents New Data for Cimzia, Investigational Bimekizumabhttps://practicaldermatology.com/news/ucb-presents-new-data-for-cimzia-investigational-bimekizumab/2460193/Data on the use of UCB’s Cimzia (certolizumab pegol), in psoriasis and psoriatic arthritis (PsA) as well as Phase 2 data for the company’s investigational molecule bimekizumab have been presented at the 28thEuropean Academy of Dermatology and Venereology congress (EADV) in Madrid. Cim
- Consumers Cite Dermatologists as Top Influencers of Cosmetic Procedure, Skin Care Choices: ASDShttps://practicaldermatology.com/news/consumers-site-dermatologists-as-top-influencers-of-cosmetic-procedure-skin-care-choices-asds/2460191/When it comes to consumer decisions on cosmetic procedures and skin care choices, dermatologists are the leading influencers, results of the 2019
- Dermira Shares Positive Data From Phase 2b Study of Lebrikizumab for Atopic Dermatitis at Fall Clinical Dermatology Conferencehttps://practicaldermatology.com/news/dermira-shares-positive-data-from-phase-2b-study-of-lebrikizumab-for-atopic-dermatitis-at-fall-clinical-dermatology-conference/2460190/Primary results from Dermira, Inc.'s Phase 2b dose-ranging study of lebrikizumab were presented during the 39th Annual Fall Clinical Dermatology Conference in Las Vegas, NV. Lebrikizumab is currently being evaluated in a Phase 3 program in adult and adolescent patients with moderat
- Data Show Long-term Benefit for Sun Pharma's Ilumyahttps://practicaldermatology.com/news/data-show-long-term-benefit-for-sun-pharmas-ilumya-1/2460189/Long-term follow-up data from ILUMYA® (tildrakizumab-asmn) Phase 3 reSURFACE 1 and 2 trials showed that the significant response rates seen in the initial 52 and 64 weeks, respectively, were maintained over four years for people with moderate-to-severe plaque psoriasis. More than half of
- Botox Hits the Big 3-0https://practicaldermatology.com/news/botox-hits-the-big-3-0/2460184/Botox is turning 30, and Allergan fêted its shining star, Botox Cosmetic, in style at a New York City bash. The event included the debut of Botox Cosmetic’s new packaging and a panel discussion featuring New York City dermatologists Macrene Alexiades-Armenakas, MD, PhD
- Allergan Shareholders Approve Proposed Acquisition by AbbViehttps://practicaldermatology.com/news/allergan-shareholders-approve-proposed-acquisition-by-abbvie/2460181/Allergan’s shareholders approved the previously announced proposed acquisition of Allergan by AbbVie Inc. More than 99 percent of the votes cast at both a special court-ordered meeting of shareholders and at an extraordinary general meeting of shareholders were in favor of the tra
- Expert Second Opinion Improves Reliability of Melanoma Diagnoseshttps://practicaldermatology.com/news/expert-second-opinion-improves-reliability-of-melanoma-diagnoses/2460179/Obtaining a second opinion from pathologists who are board certified or have fellowship training in dermatopathology may improve the accuracy and reliability of diagnosing melanoma, according to a new study in JAMA Network Open. To evaluate the impact of obtaining second o
- EADV News: Diet Linked to Acnehttps://practicaldermatology.com/news/eadv-news-diet-linked-to-acne/2460172/Consuming dairy products, sweets, soda or juice daily may increase risk for developing acne, according to research presented at the 28th European Dermato-Venereology Society Congress in Madrid. The study, which included of more than 6,700 participants across six countries in North
- It's Grant Time: La Fondation La Roche-Posay Calls for Scientific Abstractshttps://practicaldermatology.com/news/its-grant-time-la-fondation-la-roche-posay-calls-for-scientific-abstracts/2460169/Calling all residents, fellows, and practitioners within their first five years of practice: La Fondation La Roche-Posay (North American) is now accepting submissions for their 2020 grants program. Three grants for $10,000, $5,000 & $5,000 will be awarded for innovative program
- Industry News: Galderma Will Go It Alonehttps://practicaldermatology.com/news/industry-news-galderma-will-go-it-alone/2460161/It’s official. Galderma is going it alone after completion of CHF 10.2 billion acquisition of Nestlé Skin Health, first announced in May 2019. The acquisition, led by a consortium comprising the EQT VIII fund (“EQT”), Luxinva (a wholly-owned subsidiary of